Accuray(ARAY)
Focus: Accuray is a publicly traded oncology-focused medical device company specializing in directed radiation therapy platforms like CyberKnife and stereotactic radiosurgery systems. With ~$447M in FY2025 revenue, it operates at mid-cap biotech scale with a deep pipeline of radiation-based cancer indications.
Profile data last refreshed 5h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
35+63 this month
Hot — 77 jobs added in 30d
Net +63 (77 new, 14 removed). Aggressive expansion phase.
Should You Work at Accuray?
AI assessmentBest suited for engineers and oncology specialists comfortable with near-term profitability challenges in exchange for deep technical innovation in radiation therapy.
Why Work Here
- Strong oncology focus with 11 active clinical programs spanning prostate, endometrial, hepatocellular, and lung cancers—meaningful disease impact potential
- Recently inked a 10-year master research agreement with University of Wisconsin-Madison (May 2026), signaling R&D momentum and academic partnerships
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$447M
Pipeline & Clinical Trials
Stereotactic Post-operative Radiotherapy for Endometrial Cancer
Endometrial CancerClinical Trials (1)
NCT06360653a SIngle Center Study of Post-operative STEReotactic RAdiotherapY for Endometrial Cancer
N/AHelp build intelligence for Accuray
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.